Clofarabine for the Treatment of Adult Acute Myeloid Leukemia

• Tallman MS , GillilandDG, RoweJM: Drug therapy for acute myeloid leukemia.Blood106, 1154–1163 (2005).
   PubMed Web of Science ®Google Scholar
• Valk PJ , VerhaakRG, BeijenMAet al.: Prognostically useful gene-expression profiles of acute myeloid leukemia.N. Engl. J. Med.350, 1617–1628 (2004).
   PubMed Web of Science ®Google Scholar
• Sanz MA : Treatment of acute promyelocytic leukemia.Hematology Am. Soc. Hematol. Educ. Program147–155 (2006).
   Google Scholar
• Bloomfield CD , LawrenceD, ByrdJCet al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.Cancer Res.58, 4173–4179 (1998).
   PubMed Web of Science ®Google Scholar
• Frohling S , SchlenkRP, BreitruckJet al.: Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.Blood100, 4372–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Boissel N , CayuelaJM, PreudhommeCet al.: Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.Leukemia16, 1699–1704 (2002).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD , GaleRE, LangabeerSE, FrewME, BowenDT, LinchDC: Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.Blood100, 2393–2398 (2002).
   PubMed Web of Science ®Google Scholar
• Shih LY , LiangDC, FuJFet al.: Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement.Leukemia20, 218–223 (2006).
   PubMed Web of Science ®Google Scholar
• Jolkowska J , WittM: The EVI-1 gene – its role in pathogenesis of human leukemias.Leukemia Res.24, 553–558 (2000).
   PubMed Web of Science ®Google Scholar
• Lapillonne H , RennevilleA, AuvrignonAet al.: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.J. Clin. Oncol.24, 1507–1515 (2006).
   PubMed Web of Science ®Google Scholar
• Boissel N , RennevilleA, BiggioVet al.: Prevalence, clinical profile and prognosis of NPM mutations in AML with normal karyotype.Blood106, 3618–3620 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki T , KiyoiH, OzekiKet al.: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.Blood106, 2854–2861 (2005).
   PubMed Web of Science ®Google Scholar
• Preudhomme C , SagotC, BoisselNet al.: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).Blood100, 2717–2723 (2002).
   PubMed Web of Science ®Google Scholar
• Schlenk RF , DöhnerK, KrauterJet al.: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.N. Engl. J. Med.358, 1909–1918 (2008).
   PubMed Web of Science ®Google Scholar
• Mayer RJ , DavisRB, SchifferCAet al.: Intensive post-remission chemotherapy in adults with acute myeloid leukemia: cancer and leukemia group B.N. Engl. J. Med.331, 896–903 (1994).
   PubMed Web of Science ®Google Scholar
• Bishop JF , MatthewsJP, YoungGAet al.: A randomized study of high-dose cytarabine in acute myeloid leukemia.Blood87, 1710–1717 (1996).
   PubMed Web of Science ®Google Scholar
• Byrd JC , DodgeRK, CarrollAet al.: Patients with t(8;21)(q22,q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.J. Clin. Oncol.17, 3767–3775 (1999).
   PubMed Web of Science ®Google Scholar
• Bradstock KF , MatthewsJP, LowenthalRMet al.: A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.Blood105, 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Burnett AK , WheatleyK, GoldstoneAHet al.: The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial.Br. J. Haematol.118, 238–400 (2002).
   Web of Science ®Google Scholar
• Zittoun RA , MandelliF, WillemzeRet al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia.N. Engl. J. Med.332, 217–223 (1995).
   PubMed Web of Science ®Google Scholar
• Harousseau JL , CahnJY, PignonBet al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as post remission therapy in adult acute myeloid leukemia.Blood90, 2978–2986 (1997).
   PubMed Web of Science ®Google Scholar
• Cassileth PA , HarringtonDP, AppelbaumFRet al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.N. Engl. J. Med.339, 1649–1656 (1998).
   PubMed Web of Science ®Google Scholar
• Schlenk RF , CorbaciogluA, KrauterJet al.: Gene mutations as predicitive markers for post remission therapy in younger adults with normal karyotype AML.Blood108(Suppl. 1), 4 (2006).
   Google Scholar
• Godwin JE , SmithSE: Acute myeloid leukemia in the older patient.Crit. Rev. Oncol. Hematol.48(Suppl.), S17–S26 (2003).
   PubMedGoogle Scholar
• Montgomery JA , Shortnacy FowlerAT, ClaytonSD, RiordanJM, SecristJA3rd: Synthesis and biologic activity of 2´-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine.J. Med. Chem.35, 397–401 (1992).
   PubMed Web of Science ®Google Scholar
• Plunkett W , SaundersPP: Metabolism and action of purine nucleoside analogs.Pharmacol. Ther.49, 239–268 (1991).
   PubMed Web of Science ®Google Scholar
• Genini D , AdachiS, ChaoQet al.: Deoxyadenosine analogs induced programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.Blood96, 3537–3543 (2000).
   PubMed Web of Science ®Google Scholar
• Elion GB , BurgiE, HitchingsGH: Studies on condensed pyrimidine systems. IX: the synthesis of some 6-substituted purines.J. Am. Chem. Soc.74, 411–414 (1952).
   Web of Science ®Google Scholar
• Ellison RR , HollandJF, WeilMet al.: Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.Blood32, 507–523 (1968).
   PubMed Web of Science ®Google Scholar
• Vahdat L , WongET, WileMJ, RosenblumM, FoleyKM, WarrellRPJr: Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.Blood84, 3429–3434 (1994).
   PubMed Web of Science ®Google Scholar
• Krance RA , HurwitzCA, HeadDRet al.: Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.J. Clin. Oncol.19, 2804–2811 (2001).
   PubMed Web of Science ®Google Scholar
• Gandhi V , PlunkettW: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.Cancer Res.48, 329–334 (1988).
   PubMed Web of Science ®Google Scholar
• Stoeckler JD , BellCA, ParksREJr, ChuCK, FoxJJ, IkeharaM: C(2´)-substituted purine nucleoside analogs. Interactions with adenosine deaminase and purine nucleoside phosphorylase and formation of analog nucleotides.Biochem. Pharmacol.31, 1723–1728 (1982).
   PubMed Web of Science ®Google Scholar
• Reichman U , WatanabeKA, FoxJJ: A practical synthesis of 2-deoxy-2-fluoro-D-arabinofuranose derivatives.Carbohydrate Research42, 233–240 (1975).
   PubMed Web of Science ®Google Scholar
• Parker WB , ShaddixSC, ChangCHet al.: Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5´-triphosphate.Cancer Res.51, 2386–2394 (1991).
   PubMed Web of Science ®Google Scholar
• Xie KC , PlunkettW: Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β-D-arabinofuranosyl)adenine.Cancer Res.56, 3030–3037 (1996).
   PubMed Web of Science ®Google Scholar
• Lotfi K , ManssonE, SpasokoukotskajaTet al.: Biochemical pharmacology and resistance to 2-chloro-2´-deoxyadenosine, a novel analogue of cladribine in human cell lines.Clin. Cancer Res.5, 2438–2444 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ZhangJ, ShariarM, LimSH: Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens.Blood112(Suppl. 1), 147 (2008).
   Google Scholar
• Waud WR , SchmidSM, MontgomeryJA, SecristJA3rd: Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)adenine (Cl-F-ara-A).Nucleosides Nucleotides Nucleic Acids19, 447–460 (2000).
   PubMed Web of Science ®Google Scholar
• Plunkett W , GandhiV: Purine and pyrimidine nucleoside analogs. In: Cancer chemotherapy and biologic response modifiers (Annual 19). GiacconeG, SchilskyR, SondelP (Eds). Elsevier Science, BV, Amsterdam, The Netherlands, 21–45 (2001).
   Google Scholar
• Kantarjian HM , GandhiV, KozuchPet al.: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.J. Clin. Oncol.21, 1167–1173 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian H , GandhiV, CortesJet al.: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.Blood102, 2379–2386 (2003).
   PubMed Web of Science ®Google Scholar
• Lindemalm S , LiliemarkJ, GruberAet al.: Comparison of cytotoxicity of 2-chloro-2´-arabino-fluoro-2´-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.Haematologica88, 324–332 (2003).
   PubMed Web of Science ®Google Scholar
• Carson DA , WassonDB, EsparzaLM, CarreraCJ, KippsTJ, CottamHB: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2´- arabino-fluoro-2´-deoxyadenosine.Proc. Nat. Acad. Sci. USA.89, 2970–2974 (1992).
   PubMed Web of Science ®Google Scholar
• Styczynski J , GilL, DerwichKet al.: Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.Anticancer Res.29, 1643–1650 (2009).
   PubMed Web of Science ®Google Scholar
• Gandhi V , KantarjianH, FaderlSet al.: Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.Clin. Cancer Res.9, 6335–6342 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper T , KantarjianH, PlunkettW, GandhiV: Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.Nucleosides Nucleotides Nucleic Acids23, 1417–1423 (2004).
   PubMed Web of Science ®Google Scholar
• Momparler RL , FischerGA: Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside.J. Biol. Chem.243, 4298–4304 (1968).
   PubMed Web of Science ®Google Scholar
• Estey EH , KeatingMJ, McCredieKB, FreireichEJ, PlunkettW: Cellular ara-CTP pharmacokinetics, response and karyotype in newly diagnosed acute myelogenous leukemia.Leukemia4, 95–99 (1990).
   PubMed Web of Science ®Google Scholar
• Gandhi V , PlunkettW: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.Cancer Res.48, 329–334 (1998).
   Google Scholar
• Gandhi V , EsteyE, KeatingMJ, PlunkettW: Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy.J. Clin. Oncol.11, 116–124 (1993).
   PubMed Web of Science ®Google Scholar
• Spasokoukotskaja T , Sasvari-SzekelyM, KeszlerG, AlbertioniF, ErikssonS, StaubM: Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity.Eur. J. Cancer35, 1862–1867 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper T , AyresM, NowakB, GandhiV: Biochemical modulation of cytosine triphosphate by clofarabine.Cancer Chemother. Pharmacol.55, 361–368 (2005).
   PubMed Web of Science ®Google Scholar
• Faderl S , GandhiV, O’BrienSet al.: Results of a Phase I–II study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.Blood105, 940–947 (2005).
   PubMed Web of Science ®Google Scholar
• Gandhi V , EsteyE, DuM, NowakB, KeatingMJ, PlunkettW: Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.Clin. Cancer Res.1, 169–178 (1995).
   PubMed Web of Science ®Google Scholar
• Jeha S , GandhiV, ChanKWet al.: Phase I study of clofarabine (CLOFAREX™) in pediatric leukemia.Blood100(Suppl. 1), 86A (2002).
   Google Scholar
• Jeha S , GandhiV, ChanKWet al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.Blood103, 784–789 (2004).
   PubMed Web of Science ®Google Scholar
• Foran J , FaderlS, WetzlerMet al.: A Phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia.Proc. Am. Soc. Clin. Oncol.22, (2003) Abstract 2360.
   Google Scholar
• Burnett AK , RussellN, KellWJ, MilliganD, CulliganD: A Phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy.Blood104(Suppl. 1), 248A (2004).
   Google Scholar
• Burnett AK , BaccaraniM, JohnsonPet al.: A Phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable.Blood108(Suppl. 1), 130A (2006).
   Google Scholar
• Erba HP , KantarjianH, ClaxtonDFet al.: Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy.J. Clin. Oncol.26(Suppl. 1), 378S (2008).
   Google Scholar
• Erba HP , KantarjianHM, ClaxtonDFet al.: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).J. Clin. Oncol.27(Suppl. 1), 371S (2009).
   PubMedGoogle Scholar
• Foran J , TheA, DixonP, DevettenM, SekeresM: Phase I study of clofarabine with standard-dose infusional cytarabine (Ara-C) as intensive induction therapy for newly-diagnosed de novo acute myeloid leukemia in older adults aged ≥ 60 years.Blood112(Suppl. 1), 542A (2007).
   Google Scholar
• Agura ED , BerrymanR, CooperBet al.: Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity.J. Clin. Oncol.25(Suppl. 1), 372S(2007).
   Google Scholar
• Faderl S , VerstovsekS, CortesJet al.: Clofarabine and cytarabine combinations as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.Blood108, 45–51 (2006).
   PubMed Web of Science ®Google Scholar
• Burnett AK , BaccaraniM, JohnsonP, YinJ, RussellN: Clofarabine in previously untreated elderly (>65 years) AML patients with an unfavorable cytogenetic profile who are considered unfit for standard intensive chemotherapy.J. Clin. Oncol.24(Suppl. 1), 340S (2006).
   Google Scholar
• Faderl S , RavandiF, HuangXet al.: A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.Blood112, 1638–1645 (2008).
   PubMed Web of Science ®Google Scholar
• Powell B , D’AgostinoRJr, LevitanDet al.: High-dose cytarabine and clofarabine (HiDAC CLOF) in relapsed or refractory acute myeloid leukemia, a Phase 2 trial.Blood112(Suppl. 1), 676(2008).
   Google Scholar
• Thomas X , LobeI, RaffouxEet al.: Intensive consolidation with clofarabine and intermediate-dose cytarabine (CLARA) in patients with high-risk AML in first CR: the ALFA-0702 pilot study.Blood112(Suppl. 1), 675–676 (2008).
   Google Scholar
• Becker PS , EsteyE, PetersdorfSet al.: Phase I trial of clofarabine and high dose cytarabine with G-CSF priming (G-CLAC) for relapsed or refractory acute myeloid leukemia.Blood112(Suppl. 1), 1018 (2008).
   Google Scholar
• Appelbaum FR , GundackerH, HeadDRet al.: Age and acute myeloid leukemia.Blood107, 3481–3485 (2006).
   PubMed Web of Science ®Google Scholar
• Faderl S , FerrajoliA, WierdaWet al.: Clofarabine combinations as acute myeloid leukemia salvage therapy.Cancer113, 2090–2096 (2008).
   PubMed Web of Science ®Google Scholar
• Faderl S , BorthakurG, RavandiFet al.: Results of a randomized Phase 2 study of clofarabine plus cytarabine (CA) versus clofarabine plus idarubicin (CI) versus clofarabine, idarubicin, plus cytarabine (CIA) as salvage therapy in acute myeloid leukemia (AML).Blood112(Suppl. 1), 354–355 (2008).
   Google Scholar
• Yamauchi T , NowakBJ, KeatingMJ, PlunkettW: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.Clin. Cancer Res.7, 3580–3589 (2001).
   PubMed Web of Science ®Google Scholar
• Karp JE , RicklisRM, BalakrishnanKet al.: A Phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.Blood110, 1762–1769 (2007).
   PubMed Web of Science ®Google Scholar
• Burke PJ , KarpJE, BraineHGet al.: Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.Cancer Res.37, 2138–2146 (1977).
   PubMed Web of Science ®Google Scholar
• Karp JE , BurkePJ: Growth response of residual leukemia after initial drug therapy.Cancer Res.46, 4205–4207 (1986).
   PubMed Web of Science ®Google Scholar
• Woods WG , KobrinskyN, BuckleyJDet al.: Timed-sequential induction therapy improves post-remission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group.Blood87, 4979–4989 (1996).
   PubMed Web of Science ®Google Scholar
• Vaughan WP , KarpJE, BurkePJ: Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.Blood64, 975–980 (1984).
   PubMed Web of Science ®Google Scholar
• Archimbaud E , LeblondV, MichalletMet al.: Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.Blood77, 1894–1900 (1991).
   PubMed Web of Science ®Google Scholar
• Archimbaud E , ThomasX, LeblondVet al.: Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.J. Clin. Oncol.13, 11–18 (1995).
   PubMed Web of Science ®Google Scholar
• Hijiya N , GaynonPS, FernandezMet al.: Durable remissions observed in a Phase I/II study of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute leukemia.Blood112(Suppl. 1), 1006 (2008).
   Google Scholar
• Jeha S , GaynonPS, RazzoukBet al.: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.J. Clin. Oncol.24, 1917–1923 (2006).
   PubMed Web of Science ®Google Scholar
• Bonate PL , ArthaudL, StuhlerJet al.: The distribution, metabolism, and elimination of clofarabine in rats.Drug Metab. Dispos.33, 739–748 (2005).
   PubMed Web of Science ®Google Scholar
• Faderl S , Garcia-ManeroG, RavandiFet al.: Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS).Blood112(Suppl. 1), 89 (2008).
   Google Scholar
• Robak T , Lech-MarandaE, KoryckaA, RobakE: Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.Curr. Med. Chem.13, 3165–3189 (2006).
   PubMed Web of Science ®Google Scholar
• Mineishi S , MagenauJ, PawarodeAet al. Myeloablative conditioning with clofarabine and busulfan X 4 (CloBu4) is well tolerated, facilitates secure engraftment, and exhibits significant antitumor activity against nonremission hematologic malignancies including AML. Blood. 112(Suppl. 1), 749 (2008).
   Google Scholar

Website

• SEER. Surveillance, Epidemiology and End Results (SEER) website. http:seer.cancer.gov.
   Google Scholar